|
Regulatory |
An In-Depth Exploration into the Best Practices Considerations of the E14/S7B Q&A Guidance |
Regulatory |
2024 |
Prior H et al (2009). Journal of Pharmacological and Toxicological Methods 60: 167-173. doi: 10.1016/j.vascn.2009.06.001 |
|
Cardiovascular |
Mini-Course: Cardiovascular Safety in Drug Development |
Cardiovascular |
2024 |
Prior H et al (2009). Journal of Pharmacological and Toxicological Methods 60: 167-173. doi: 10.1016/j.vascn.2009.06.001 |
|
Toxicology |
Toxicology for the Safety Pharmacologist |
General, Toxicology |
2024 |
Prior H et al (2009). Journal of Pharmacological and Toxicological Methods 60: 167-173. doi: 10.1016/j.vascn.2009.06.001 |
|
General |
Advances in In Vitro/Ex Vivo Assays |
General |
2020 |
Prior H et al (2009). Journal of Pharmacological and Toxicological Methods 60: 167-173. doi: 10.1016/j.vascn.2009.06.001 |
|
Cardiovascular |
Blood Pressure: Mechanisms of Control, Beat-to-Beat Analysis and Translation to the Clinic |
Cardiovascular |
2023 |
Prior H et al (2016). Journal of Pharmacological and Toxicological Methods 81: 75-87. doi.org/10.1016/j.vascn.2016.03.004 |
|
CNS |
CNS Biomarkers of Mood Disorders and Drug Abuse: Where Are We? |
CNS |
2021 |
Prior H et al (2016). Journal of Pharmacological and Toxicological Methods 81: 75-87. doi.org/10.1016/j.vascn.2016.03.004 |
|
CNS |
Drug Abuse Liability Testing |
CNS |
2011 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
How do the 3R principles apply in Safety Pharmacology Core Battery? |
General |
2022 |
Skinner M et al (2019). Journal of Pharmacological and Toxicological Methods 96:87-94. doi: 10.1016/j.vascn.2019.02.005 |
|
Regulatory |
ICH E14/S7B Q7As Implementation for Practitioners |
Regulatory |
2022 |
Skinner M et al (2019). Journal of Pharmacological and Toxicological Methods 96:87-94. doi: 10.1016/j.vascn.2019.02.005 |
|
General |
Imaging Technologies in Safety and Preclinical Research |
General |
2020 |
Skinner M et al (2019). Journal of Pharmacological and Toxicological Methods 96:87-94. doi: 10.1016/j.vascn.2019.02.005 |
|
General |
Immunotherapy – Insights Into Immunogenicity and Immunotoxicology |
General |
2021 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Microsampling Techniques and Novel Applications in Exposure Assessment |
General |
2011 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Mini Course: Introduction and Overview to the Field of Safety Pharmacology |
General |
2022 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Mini-Course: Organoids and their Applications |
General |
2023 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
Regulatory |
Nonclinical Components of Integrated QTc Assessment Proposed in Emerging ICH E14/S7B Q&As |
Regulatory |
2021 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
CNS |
Practical Application of CNS Safety Assessments: The Why, When, and How |
CNS |
2023 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
SAFETY Biomarkers—What Every Safety Pharmacologist Should Know! |
General |
2012 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Safety of Novel Therapeutic Modalities: Scientific Considerations and Regulatory Guidance |
General |
2021 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Safety Pharmacology Considerations for Large Molecule and Novel Therapeutic Modalities |
General |
2022 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Safety Pharmacology Endpoints in Toxicology Studies |
General |
2012 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
Supplemental |
Safety Pharmacology of the Senses |
Supplemental |
2020 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
Supplemental |
Supplemental Safety Pharmacology Studies |
Supplemental |
2011 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General, Statistics |
The Power of Safety Pharmacology in Drug Development |
General, Statistics |
2020 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Translational Science in Safety Pharmacology and Implications in the Clinic – Where Are We? |
General |
2021 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Use of Artificial Intelligence (AI)/Machine Learning (ML) in Drug Development and Safety |
General |
2020 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General, Statistics |
Variability, Uncertainty and Probability in Safety Pharmacology Decision Making |
General, Statistics |
2019 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |
|
General |
Watch Your Tone: Intended and Unintended Effects on the Autonomic Nervous System and the Downstream Impact on Key Organ Systems |
General |
2020 |
Berridge B et al (2016). iLAR journal 57: 120–132. doi: 10.1093/ilar/ilw028 |